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http://dx.doi.org/10.1016/j.jfma.201Interferon-based regimen has been used to treat hepatitis D virus (HDV) super-infection on top
of hepatitis B virus (HBV) carriers; however, viral relapse is frequent after stopping therapy.
Recently, quantitative hepatitis B surface antigen (qHBsAg) was introduced to help the man-
agement of chronic hepatitis B (CHB). Little is known about its role in the treatment of HBV
and HDV dual infection. Herein, we reported a 45-year-old male HBV carrier with HDV co-infec-
tion who received combination therapy of pegylated-interferon a-2a plus entecavir. The
qHBsAg level was adopted as the treatment guidance and a consolidation therapy of 12 months
was continued after HBsAg loss. The patient achieved HBsAg seroconversion with HDV RNA un-
detectable after 35 months of combination therapy and sustained therapeutic response 12
months post-therapy. Therefore, personalized response-guided therapy by using qHBsAg may
be an option for the treatment for HBV and HDV dual infection.
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Figure 1 The treatment responses of dual HBV-HDV infection
in this patient.
Interferon plus entecavir for hepatitis B and D 1141treatment of HBV and HDV dual infection. Herein, we report
an HBV carrier with HDV dual infection, who received com-
bination therapy of pegylated-interferon a-2a plus enteca-
vir. The qHBsAg level was adopted as the treatment
guidance with a good sustained response.
A 45-year-old Taiwanese man with HBeAg-negative geno-
type C chronic hepatitis B, had a persistent elevation of serum
alanine aminotransferase (ALT), despite effective treatment
with oral entecavir (0.5 mg) for 13months (with undetectable
HBV-DNA level for 10months). At his first visit, laboratory data
showed ALT elevation (142 U/L, normal limit: <41 U/L), pos-
itive HBsAg (>250 IU/mL), negative anti-HCV, and HBV-DNA
level <10 IU/mL. Other etiologies of hepatitis including alco-
holic, autoimmune, cholestatic, hereditary, drug and steato-
hepatitis were excluded by clinical and laboratory evidence.
The liver histology revealed advanced fibrosis (Metavir score:
F3) with active inflammation (Histology-Activity-Index score:
10). Serum qualitative HDV-RNA was positive by the polymer-
ase chain reaction (PCR). With the diagnosis of HBV and HDV
dual infection, the patient received combination therapy of
weekly pegylated-interferon a-2a 180 mg, plus daily entecavir
(0.5 mg) since September 2008. Declines of ALT and qHBsAg
levels were noted and followed by HBsAg loss at 23 months of
combination therapy. In addition, serum HDV-RNA became
undetectable after 13 months of therapy. Moreover,
improvementofhepatic fibrosiswas documentedbyFibroscan(5.7 kPa, corresponding to Metavir score: F0eF1). A consoli-
dation therapy after HBsAg loss was administered for 1 more
year.HBsAgseroconversion,withaprotective level ofanti-HBs
and ALT normalization, was achieved at 25 months of treat-
ment. Thus, a sustained treatment response was noted for
more than 12 months after stopping combination therapy
(Fig. 1).
Conventional or pegylated-interferon-a is the only agent
for the treatment of HBV and HDV dual infection; however,
the sustained HDV clearance rate was only 25e30% after 1
year of treatment with a high viral relapse.3 The addition of
oral ribavirin, adefovir, or lamivudine to interferon did not
show additional benefits.4 The efficacy of entecavir mono-
therapy for HDV infection was poor, probably because of
short treatment duration and no HBsAg decline during
therapy.5 The major challenge for the treatment of HBV and
HDV dual infection is the higher rate of viral relapse after
discontinuation of therapy. Theoretically, the best thera-
peutic endpoint of HBV and HDV dual infection is HBsAg
seroclearance. If serumHBsAg remains detectable in treated
patients, the residual intrahepatic HDV may reactivate into
a full blown infection and recapitulate hepatitis D.3
In this case report, the combination of pegylated inter-
feron a-2a plus entecavir might be effective for the treat-
ment of HBV and HDV dual infection. In addition, serum
qHBsAg level may be a good guidance for treatment dura-
tion and 1 year consolidation therapy post HBsAg serocon-
version could be considered to increase the sustained
response rate.References
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